

Mumbai-based startup Epigeneres Biotech raises \$6 M in Series B funding

18 January 2022 | News

The latest round of investment will go towards expanding its lab facilities, scaling operations, and developing an AI platform



Mumbai-based Epigeneres Biotech, the exclusive licensee in India of Singapore-based Tzar Labs, has raised \$6 million in a Series B funding round.

Lead investors in this round include Kotak Investment Advisors, Moez Daya (of Satya Capital), and LetsVenture Angel Fund. Other investors include Ashish Kacholia, East River Advisors, One Decacorn, Nandita Advisors, and Chockalingam Valliappa, to name a few.

In May 2021, Epigeneres Biotech announced their early detection cancer test (co-developed with Tzar Labs, Singapore - a specialised molecular diagnostic company), with a pioneering breakthrough in RNA bio-markers technology which can even detect cancer in Stage Zero (i.e., before tumour formation).

With initial approvals in place, the latest round of investment will go towards expanding its Lab facilities, scaling operations, and development of an AI platform to launch the service in India - a world first. And, continue bringing the best diagnostic technology to patients and providers.